MARKET INTELLIGENCE·M&A
Moderna Restructures Leadership for 2027-2028 Product Launches: Key Implications for Supply Chain and Regulatory Affairs
Moderna is strategically realigning its leadership, appointing Ester Banque as CCO and expanding Stephen Hoge's role to oversee commercial, manufacturing, and R&D. This internal restructuring prepares Moderna for launching up to three new products between 2027 and 2028. The move signals a drive for integrated operations, impacting procurement, supply chain, and regulatory engagement for future market entries.
90-Day Activity